Q86 · Healthcare · 3 regions
Oncology novel active substance (NAS) launches (cumulative)
Global: 132 in 2020–2024, +67.1% on 2015–2019.
- 132 Latest · Global · 2020–2024
- +67.1% vs 2015–2019
- Irregular Release cadence
- 6 Records · 3 regions · 2005–2024
Verified 27 Sep 2026 · 1 publisher
Across regions
2 regions on one axis, spaced by time. Below it, selected latest values by region. Forecasts are dashed with hollow markers; the underlying values are one click away under the chart.
Oncology novel active substance (NAS) launches (cumulative) by region
2 of 3 regions drawn, 2005–2024 to 2020–2024; latest values are ranked below
No figure published for these periods
Oncology novel active substance (NAS) launches (cumulative) by region
Latest value per region, 2020–2024
View the underlying data
| Category | Source | Type | Value |
|---|---|---|---|
| Global | IQVIA | Actual | 132 |
| United States | IQVIA | Actual | 85 |
| China | IQVIA | Actual | 84 |
Every record
6 records · 3 regions · 2005–2024. Each period links to its record: the value, its source evidence and original document.
| Period | Value | Source | Type |
|---|---|---|---|
| Global 3 records | |||
| 2020–2024 | 132 | IQVIA · 31 Dec 2024 | |
| 2015–2019 | 79 | IQVIA · 31 Dec 2019 | |
| 2005–2024 | 282 | IQVIA · 31 Dec 2024 | |
| United States 1 record | |||
| 2020–2024 | 85 | IQVIA · 31 Dec 2024 | |
| China 2 records | |||
| 2020–2024 | 84 | IQVIA · 31 Dec 2024 | |
| 2015–2019 | 37 | IQVIA · 31 Dec 2019 | |
Download this data
Every file carries its provenance: the CSV has a source column per row, and the chart images print the publisher, the licence and this page's address under the drawing. Source: IQVIA. Licence: CC BY 4.0.
Embed this chart
For automatic sizing and multiple charts, see the JavaScript embed guide.
Free to embed anywhere, including commercially. The attribution bar is part of the chart. The link under the frame is optional: keep it, remove it or mark it rel="nofollow".
Use and publication rights
- View, cite and link: free
Quote any number, cite this page or a single record, and link to it anywhere.
- Copy, chart and republish: free with attribution
The data is published under CC BY 4.0, commercial use included. Credit StatOrigin and the original publisher (IQVIA); the chart files already carry that line.
- The source documents: the publisher's terms
Figures are facts read from the publishers' own documents. The documents themselves, their text and design, stay under each publisher's terms; follow the source links for those.
How this measure is built
- Definition
- Total number of oncology novel active substances launched over a stated multi-year period.
- Measure
- One slice of Novel active substance launches ( basis: cumulative, form: count, segment: oncology ) . Total number of novel active substances launched on the market. Region and period are columns on every record, not slices.
- Limitations
- Values are shown as published; StatOrigin does not revise, fill gaps or convert currencies.
- Verification
- Each value, unit, period and place was checked against its source evidence before publication. See the methodology and the corrections process.
Sources · 1 document
| Document | Publisher | Published | Data points |
|---|---|---|---|
| Global Oncology Trends 2025 | IQVIA | — | 6 |
Other slices of novel active substance launches
- Novel active substance launches 6
- Oncology novel active substance (NAS) launches (annual) 3 oncology
- First-in-class novel active substance launches 2 first in class
- Novel active substance launches, five-year total 2 cumulative
- Chemically synthesized share of new medicine launches 1 chemical
- Cumulative cell and gene therapy launches 1 cumulative · cell and gene therapy
- Domestic-only oncology NAS launches (cumulative) 1 cumulative · domestic · oncology
- Expected annual novel active substance launches (lower bound) 1 forecast low
- Expected annual novel active substance launches (upper bound) 1 forecast high
- Expected cumulative novel active substance launches (lower bound) 1 cumulative · forecast low
- Expected cumulative novel active substance launches (upper bound) 1 cumulative · forecast high
- Genetically engineered share of new medicine launches 1 biologic
Frequently asked questions
What is the latest oncology novel active substance (NAS) launches (cumulative)?
Global: 132 in 2020–2024, +67.1% on 2015–2019.
Where does this data come from?
From 1 document published by IQVIA. Every figure on this page links to its record, which preserves the original source evidence.
How often is it updated?
Irregularly: the publishers behind this measure do not release it on a fixed schedule. A new figure appears here once it is published and verified.
Can I use this data?
Yes. StatOrigin publishes it under CC BY 4.0: you may copy, chart and republish it, including commercially, with attribution to StatOrigin and to the original publisher.
Cite this page
Cite the page as a data set, or open any record to cite one figure: each record carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). Oncology novel active substance (NAS) launches (cumulative) [Data set]. Retrieved October 28, 2026, from https://statorigin.org/indicators/oncology-novel-active-substance-nas-launches-cumulative
"Oncology novel active substance (NAS) launches (cumulative)." StatOrigin, 2026, https://statorigin.org/indicators/oncology-novel-active-substance-nas-launches-cumulative. Accessed 28 Oct. 2026.
StatOrigin. "Oncology novel active substance (NAS) launches (cumulative)." Data set, 2026. Accessed October 28, 2026. https://statorigin.org/indicators/oncology-novel-active-substance-nas-launches-cumulative.
@misc{statorigin_oncology_novel_active_substance_nas_launches_cumulative_2026, title = {Oncology novel active substance (NAS) launches (cumulative)}, author = {{StatOrigin}}, year = {2026}, url = {https://statorigin.org/indicators/oncology-novel-active-substance-nas-launches-cumulative}, note = {Data set. Accessed 2026-10-28} }